يعرض 1 - 10 نتائج من 51 نتيجة بحث عن '"Colorectal cancer metastases"', وقت الاستعلام: 1.71s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية

    المصدر: Siberian journal of oncology; Том 23, № 1 (2024); 155-161 ; Сибирский онкологический журнал; Том 23, № 1 (2024); 155-161 ; 2312-3168 ; 1814-4861

    وصف الملف: application/pdf

    العلاقة: https://www.siboncoj.ru/jour/article/view/2968/1206Test; Поликарпов А.А., Таразов П.Г., Гранов Д.А., Полысалов В.Н. Рентгенэндоваскулярные процедуры в лечении больных с нерезектабельными метастазами колоректального рака в печени. Российский онкологический журнал. 2014; 19(4): 40–1.; Adam R., Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019; 3(1): 50–6. doi:10.1002/ags3.12227.; Tzeng C., Aloia T. Colorectal Liver Metastases. J Gastrointest Surg. 2012; 17: 195–201. doi:10.1007/s11605-012-2022-3.; Gruber-Rouh T., Naguib N., Eichler K., Ackermann H., Zangos S., Trojan J., Beeres M., Harth M., Schulz B., Nour-Eldin A., Vogl T.J. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period. Int J Cancer. 2013; 134: 1225–31. doi:10.1002/ijc.28443.; Alexander H.R., Bartlett D.L., Libutti S.K., Pingpank J.F., Fraker D.L., Royal R., Steinberg S.M., Helsabeck C.B., Beresneva T.H. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol. 2009; 16(7): 1852–9. doi:10.1245/s10434-009-0482-9.; Ben-Shabat I., Hansson C.,Eilard M., Cahlin C., Rizell M., Lindnér P., Mattsson J., Bagge R. Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma. J Vis Exp. 2015; (95): 52490. doi:10.3791/52490.; van Iersel L.B.J., Koopman M., van de Velde C.J.H., Mol L., van Persijn van Meerten E.L., Hartgrink H.H., Kuppen P.J.K., Vahrmeijer A.L., Nortier J.W.R., Tollenaar R.A.E.M., Punt C., Gelderblom H. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol. 2010; 21(8): 1662–7. doi:10.1093/annonc/mdp589.; Hafström L.R., Holmberg S.B., Naredi P.L., Lindnér P.G., Bengtsson A., Tidebrant G., Scherstén T.S. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol. 1994; 3(2): 103–8. doi:10.1016/0960-7404(94)90005-1.; Huibers A., DePalo D.K., Perez M.C., Zager J.S., Olofsson Bagge R. Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver. Clin Exp Metastasis. 2023. doi:10.1007/s10585-023-10234-6.; Olofsson Bagge R., Nelson A., Shafazand A., All-Eriksson C., Cahlin C., Elander N., Helgadottir H., Kiilgaard J.F., Kinhult S., Ljuslinder I., Mattsson J., Rizell M., Sternby Eilard M., Ullenhag G.J., Nilsson J.A., Ny L., Lindnér P. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). J Clin Oncol. 2023; 41(16): 3042–50. doi:10.1200/JCO.22.01705.; Bethlehem M.S., Katsarelias D., Olofsson Bagge R. Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases. Cancers (Basel). 2021; 13(18): 4726. doi:10.3390/cancers13184726.; Eggermont A.M., van IJken M.G., van Etten B., van der Sijp J.R., ten Hagen T.L., Wiggers T., Oudkerk M., de Boeck G., de Bruijn E.A. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology. 2000; 47(33): 776–81.; Dewald C.L.A., Becker L.S., Maschke S.K., Meine T.C., Alten T.A., Kirstein M.M., Vogel A., Wacker F.K., Meyer B.C., Hinrichs J.B. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. Clin Exp Metastasis. 2020; 37(6): 683–92. doi:10.1007/s10585-020-10057-9.; Vogel A., Ochsenreither S., Zager J.S., Wacker F., Saborowski A. Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence. Cancer Treat Rev. 2023; 113: 102501. doi:10.1016/j.ctrv.2022.102501.; Rowcroft A., Loveday B.P.T., Thomson B.N.J., Banting S., Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020; 22(4): 497–505. doi:10.1016/j.hpb.2019.11.002.; https://www.siboncoj.ru/jour/article/view/2968Test

  3. 3
    دورية أكاديمية

    المصدر: Journal of Clinical Medicine; Volume 10; Issue 17; Pages: 3867

    وصف الملف: application/pdf

    العلاقة: Gastroenterology & Hepatopancreatobiliary Medicine; https://dx.doi.org/10.3390/jcm10173867Test

  4. 4
    دورية أكاديمية

    المصدر: Journal of Clinical Medicine; Volume 10; Issue 13; Pages: 2778

    وصف الملف: application/pdf

    العلاقة: Gastroenterology & Hepatopancreatobiliary Medicine; https://dx.doi.org/10.3390/jcm10132778Test

  5. 5
  6. 6
    دورية أكاديمية
  7. 7
  8. 8
  9. 9
    دورية أكاديمية

    المساهمون: Zanetto, A., Shalaby, S., Gambato, M., Germani, G., Senzolo, M., Bizzaro, D., Russo, F. P., Burra, P.

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34501314; info:eu-repo/semantics/altIdentifier/wos/WOS:000694300700001; volume:10; issue:17; firstpage:3867; journal:JOURNAL OF CLINICAL MEDICINE; http://hdl.handle.net/11577/3401822Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85113759932

  10. 10
    دورية أكاديمية

    المساهمون: Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service de Radiologie Nantes, Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Département de Pathologie CHU Nantes, Unité de Pharmacie ICO, Saint Herblain, Institut de Cancérologie de l'Ouest Angers/Nantes (UNICANCER/ICO), UNICANCER-UNICANCER, Délégation à la Recherche Clinique et à l'Enovation Nantes ((DRCI)), Hôtel-Dieu-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Immunomedics Inc. Morris Plains, NJ, USA, IBC Pharmaceuticals Inc Morris Plains, NJ, USA, ARRONAX - (GIP) Groupement d'Intérêt Public Saint-Herblain (Institut de Recherche Public), ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011)

    المصدر: ISSN: 1619-7070.